STAT+: Novo underwhelmed by drug it once fought Pfizer for

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Gene therapies can now cure disease, but America still hasn’t figured out how to pay for them. Is there a better way? Also, Novo executives are downplaying a once-coveted obesity drug, Incyte is making a $2 billion blood disease bet, and new data suggest Boehringer’s obesity contender may struggle to stand out in an increasingly crowded market.

The need-to-know this morning

• Roche is partnering with Nurix Therapeutics to co-develop an experimental antibody treatment that works by degrading, or eliminating, a protein called BTK that is associated with blood cancer and other diseases. 
• Treeline Biosciences, the developer of early-stage cancer medicines co-founded by biotech entrepreneur Josh Bilenker, is going public via a reverse merger with Standard BioTools. 

Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients.

Continue to STAT+ to read the full story…